Loading
A phase 1/2 trial of Pembrolizumab, Lenvatinib in cervical cancer and non-small-cell lung cancer, run by GI Innovation, Inc., now recruiting.
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT04977453 by GI Innovation, Inc., with 317 participants planned, started 2021-08-02 and due to reach its primary completion in 2028-06-30. Interventions recorded: GI-101, Pembrolizumab (KEYTRUDA®), Lenvatinib, GI-101A. Conditions listed: Advanced Solid Tumor, Metastatic Solid Tumor, Cervical Cancer, Urothelial Carcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Lenvatinib, Anti-angiogenic therapy, Pembrolizumab, Small-molecule kinase inhibitors.
Shares Lenvatinib, Anti-angiogenic therapy, Pembrolizumab, Small-molecule kinase inhibitors.
Shares Lenvatinib, Anti-angiogenic therapy, Pembrolizumab, Small-molecule kinase inhibitors.
Shares Lenvatinib, Anti-angiogenic therapy, Pembrolizumab, Small-molecule kinase inhibitors.
Shares Lenvatinib, Anti-angiogenic therapy, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Lenvatinib, Anti-angiogenic therapy, Pembrolizumab, Small-molecule kinase inhibitors.
Shares Lenvatinib, Anti-angiogenic therapy, Pembrolizumab, Small-molecule kinase inhibitors.
Shares Lenvatinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/